Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.
You may also be interested in...
Teva’s New CEO Levin Urges “Fiscal, Strategic Discipline,” Reduces 2012 Guidance
In a hastily scheduled, between-quarters update, Teva takes down its 2012 guidance issued only five months ago. New CEO Jeremy Levin promises a full strategic rendering by year end, announces long-time Teva exec Allan Oberman as new head of U.S. generics and establishment of a global compliance committee.
Forest’s Antipsychotic Cariprazine Clears Last Clinical Hurdle To Double NDA Filing In 2012
Specialty pharma has data in hand to support a double filing of novel antipsychotic cariprazine this year for acute exacerbation of schizophrenia and bipolar mania, with studies ongoing to support two additional indications in MDD.
Generic Opportunities In 2012 Diluted By Shared Exclusivities
Despite the patent cliff, 2012 is one of the final years of blockbusters going generic, leaving the large generic companies to establish their place in the morphing market.